Epicentre   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Paris France (1986)
Status: Acquired by Illumina, Inc. (2011)

Organization Overview

First Clinical Trial
2001
NCT00330148
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Epicentre | Epicentre, Paris, France.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacterial Infections (Phase 3)

Communicable Diseases (Phase 3)

Fever (Phase 4)

Gastroenteritis (Phase 3)

Gram-Positive Bacterial Infections (Phase 3)

Hemorrhagic Fever, Ebola (Phase 3)

Infections (Phase 3)

Leg Injuries (Phase 4)

Malaria (Phase 4)

Malaria, Cerebral (Phase 2)

Malaria, Falciparum (Phase 4)

Malnutrition (Phase 4)

Meningitis (Phase 4)

Meningitis, Meningococcal (Phase 4)

Meningococcal Infections (Phase 4)

Mycobacterium Infections (Phase 3)

Severe Acute Malnutrition (Phase 4)

Trypanosomiasis (Phase 3)

Trypanosomiasis, African (Phase 3)

Tuberculosis (Phase 3)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Virus Diseases (Phase 3)

Wounds and Injuries (Phase 4)

Yellow Fever (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 28
  • # of Trial APIs: 43